Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)-Reference-Cited by-同舟云学术

Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)

Published:2024-04-13 Issue:2 Volume:13 Page:369-378
ISSN:2193-8261
Container-title:Cardiology and Therapy
language:en
Short-container-title:Cardiol Ther

Author:

Attal Sepideh,Kemner Jason,Alvir Jose,Barth Sebastian,Schuessler Sofia

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40119-024-00365-6.pdf

Reference24 articles.

1. Kato T, Ines M, Minamisawa M, et al. Tafamidis medication adherence and persistence in patients with transthyretin cardiac amyloidosis (ATTR-CM) in Japan. ESC Heart Fail. 2024. In press.

2. Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol. 2006;6:214–20. https://doi.org/10.1016/j.coph.2005.10.005.

3. Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21:221–4. https://doi.org/10.3109/13506129.2014.964858.

4. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97:75–84. https://doi.org/10.1136/hrt.2009.190405.

5. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16. https://doi.org/10.1056/NEJMoa1805689.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tafamidis use in amyloid cardiomyopathy;Journal of Prescribing Practice;2024-06-02